BioNTech's CEO Sees Vaccine Covering New Strain as Analysts Rework the Pipeline and Three Plants Head for Closure

Sahin says vaccine likely protects against the UK variant, but analyst cuts two programs and BioNTech plans to close three German sites by 2028.

BioNTech CEO Ugur Sahin moved to calm nerves over the weekend, saying it is "highly likely" that his company's COVID-19 vaccine also protects against the more infectious coronavirus variant circulating in southeast England. The caveat came quickly: Sahin stressed that detailed scientific studies are still needed to produce reliable data and to prove the protective effect beyond doubt.

His remarks land at a moment when the market is already busy reassessing BioNTech's longer-term research bets. Analyst Ahmad cut both FixVac for melanoma and the iNeST program against adjuvant colorectal cancer from his model after the company discontinued the two clinical efforts. The pipeline cleanup was the trigger for that revision.

Morgan Stanley Trims, Others Stay on the Sidelines

Morgan Stanley's Terence Flynn had already made a smaller adjustment on October 7, nudging his price target to $114 from $115 while keeping an "Overweight" rating. Other market watchers initiated coverage of the stock with a neutral hold recommendation.

On the operational side, BioNTech confirmed on September 28 that it plans to gradually give up its production sites in Tübingen, Marburg and Idar-Oberstein. The three closures will be staggered and completed by 2028. The step became unavoidable after sales efforts came up empty and no buyers could be found for the affected facilities.

A Pre-Arranged Exit at the Top

The CEO's own holdings also drew attention. Sahin's share sale was executed under a pre-set Rule 10b5-1 trading plan, and the transaction left his directly held stake at zero. That does not mark a departure by the co-founder: through Medine GmbH, he still indirectly holds 39,218,111 BioNTech shares.

Such automated selling programs are common at US-listed companies, letting executives sell without raising suspicions of insider trading. Market watchers still track them closely, since shifts in reported holdings can sway retail sentiment.

Sector Tailwind Without a Company Catalyst

Support came from the broader sector, where a New York Times report about a planned US initiative to speed up personalized cancer vaccines lifted BioNTech shares. According to media accounts, the gain was a sector-wide move among vaccine makers rather than a specific operational announcement from BioNTech itself.

Despite the occasional positive headline, the combination of these factors has kept the Mainz-based company from launching into a sustained upward trend for now.

Trading Around the 200-Day Line

The stock ended the previous session at EUR 85.90, down 0.7%, leaving it 1.4% above its 200-day moving average of EUR 84.68. As long as fresh company-specific catalysts are absent, consolidation around that closely watched trend line looks likely to persist.